Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study

References

• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Bladé J, Cibeira MT, Fernández de Larrea C, et al. Multiple myeloma. Ann Oncol. 2010;21 Suppl 7:vii313–9.
   PubMedGoogle Scholar
• Dimopoulos MA, Terpos E. Multiple myeloma. Ann Oncol. 2010;21(Suppl 7):vii143–50.
   PubMedGoogle Scholar
• Phekoo KJ, Schey SA, Richards MA, et al.; on behalf of Consultant Haematologists, South Thames Haematology Specialist Committee. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in the UK, Consultant Haematologists, South Thames Haematology Specialist Committee. Br J Haematol. 2004;127(3):299–304.
   PubMedGoogle Scholar
• Sant M, Allemani C, Tereanu C, et al.; HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–3734.
   PubMed Web of Science ®Google Scholar
• Gay F, Engelhardt M, Terpos E, et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica. 2018;103(2):197–211.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Goldschmidt H, Rosiñol L, et al. Bortezomib-based versus non bortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Cin Oncol. 2013;31(26):3279–3287.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48–e548.
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420.
   PubMed Web of Science ®Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
   PubMed Web of Science ®Google Scholar
• Hungria VT, Maiolino A, Martinez G, et al.; International Myeloma Working Group Latin America. Observational study of multiple myeloma in Latin America. Ann Hematol. 2017;96(1):65–72.
   PubMed Web of Science ®Google Scholar
• Hungria VT, Martínez‐Baños DM, Peñafiel CR, et al. Multiple myeloma treatment patterns and clinical outcomes in Latin America: Haemato‐Oncology (HOLA) Observational Study, 2008–2016. Br J Haematol. 2020;188(3):383–393.
   PubMed Web of Science ®Google Scholar
• Peña C, Rojas C, Rojas H, et al. Survival of 1,103 Chilean patients with multiple myeloma receiving different therapeutic protocols from 2000 to 2016. Rev Méd Chile. 2018;146(7):869–875.
   PubMed Web of Science ®Google Scholar
• Riva E, Bove V, Villano F, et al. From guidelines to real-world: results from the National Multiple Myeloma Registry in Uruguay on 222 newly diagnosed multiple myeloma patients from 2012 to 2015. Curr Med Res Opin. 2019;8:1–7.
   Google Scholar
• Abello V, Idrobo H, Sossa CL, et al. The Status of Multiple Myeloma in Colombia: First Report of the Colombian Registry for Hemato-Oncological Diseases (RENEHOC). Asociación Colombiana de Hematologia y Oncologia (ACHO). Blood. 2018;132(Supplement 1):5597–5597.
   Google Scholar
• Ruiz-Argüelles GJ, Gómez-Rangel JD, Ruiz-Delgado GJ, et al. Multiple myeloma in Mexico: a 20-year experience at a single institution. Arch Med Res. 2004;35(2):163–167.
   PubMed Web of Science ®Google Scholar
• Belizán JM, Cafferata ML, Belizán M, et al. Health inequality in Latin America. Lancet. 2007;370(9599):1599–1600.
   PubMed Web of Science ®Google Scholar
• Belló M, Becerril-Montekio VM. Sistema de salud de Argentina. Salud Publica Mex. 2011;53(2):S96–S108.
   PubMedGoogle Scholar
• Aran D, Laca H. Sistema de salud de Uruguay. Salud Publica Mex. 2013;53(2):S265–S274.
   Google Scholar
• Guerrero R, Gallego AI, Becerril-Montekio V, et al. Sistema de salud de Colombia. Salud Publica Mex. 2011;53 (supl 2):S144–S155.
   PubMedGoogle Scholar
• Lucio R, Villacrés N, Henríquez R. Sistema de salud de Ecuador. Salud Publica Mex. 2011;53 (Suppl 2):S177–S187.
   PubMed Web of Science ®Google Scholar
• Gómez-Dantés O, Sesma S, Becerril VM, et al. Sistema de Salud de México. Salud Publica Mex 2011. 53(Suppl 2):S220–S223.
   Google Scholar
• Riva E, Schutz N, Peña C, et al. Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Results from a Latin American survey. GELAMM (Grupo de Estudio Latino Americano de Mieloma Múltiple). Ann Hematol. 2020;99(5):1025–1030.
   PubMed Web of Science ®Google Scholar
• Pessoa de Magalhães Filho RJ, Crusoe E, Riva E, et al. Analysis of availability and access of anti-myeloma drugs and impact on the management of multiple myeloma in Latin American Countries. Clin Lymphoma Myeloma Leuk. 2019;19(1):e43–e50.
   PubMed Web of Science ®Google Scholar
• Tarín-Arzaga L, Arredondo-Campos D, Martínez-Pacheco V, et al. Impact of the affordability of new agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico. Cancer. 2018;124(9):1946–1953.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Kaufman JL, Behera M, et al. Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. Cancer. 2013;119(23):4119–4128.
   PubMed Web of Science ®Google Scholar
• de Queiroz Crusoe E, Higashi F, Padilha MP, et al. Outcomes of autologous transplantation for multiple myeloma according to different induction regimens. Rev Bras Hematol Hemoter. 2014;36(1):19–24.
   PubMedGoogle Scholar
• Gale RP, Seber A, Bonfim C, et al. Haematopoietic cell transplants in Latin America. Bone Marrow Transplant. 2016;51(7):898–905.
   PubMed Web of Science ®Google Scholar
• Paquin AR, Kumar SK, Buadi FK, et al. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer J. 2018;8(12):125.
   PubMedGoogle Scholar
• Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895–905.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–1791.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770–1781.
   PubMed Web of Science ®Google Scholar
• Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the phase III myeloma XI study. Blood. 2016;128(22):1143–1143.
   Web of Science ®Google Scholar
• Attal M, Harousseau J-L, Leyvraz S, for the Inter-Groupe Francophone du Myelome (IFM), et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108(10):3289–3294.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Gregory WM, Davies FE, et al.; on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012;119(1):7–15.
   PubMed Web of Science ®Google Scholar